| 肝细胞癌治疗药物研究进展 |
| |
| 引用本文： | 廖明媚,胡曼（综述）,何剪太（审校）. 肝细胞癌治疗药物研究进展[J]. 世界肿瘤杂志, 2008, 7(3): 229-232 |
| |
| 作者姓名： | 廖明媚 胡曼（综述） 何剪太（审校） |
| |
| 作者单位： | [1]中南大学卫生部肝胆肠外科研究中心,湖南长沙410008 [2]中南大学湘雅医学院,湖南长沙410078 |
| |
| 摘 要： | 肝细胞癌（HCC）死亡率高，晚期治疗手段有限，生存期短，对多种化疗药物易产生多药耐药。近年来HCC的分子靶向药物研究取得到了很大的进展，且与其它化疗药物联合作用有着很好的研究前景。本文对目前肝细胞癌的治疗药物进行了归纳与阐述，深入探讨各类药物在未来发展的潜力以及可能面对的挑战，为延长晚期肝癌生存期寻求有效的综合治疗方案。
|
| 关 键 词： | 肝细胞癌 治疗 分子靶向药物 多药耐药 |
The research development in drugs for hepatocellular carcinoma |
| |
| Affiliation: | UAO Ming-mei, HU Man, HE Jian-tai (1 National heptobilliary ＆ enteric research center, Ministry of Health, Changsha, Hunan, 410008; 2 Central South University, Xiangya School of Medicine. Changsha, Hunan, 410008) |
| |
| Abstract: | The mortality rate of hepatocellular carcinoma （HCC） is high, the treatment method in advanced period is limited, survival time is short, and it＇s easy to produce multi-drug resistance to many kinds of chemotherapy drugs . In recent years the great progress has been made in the research of HCC molecular target drug, it has good research prospect with other chemotherapeutic agents in Combination treatment. This article has classified and described the drugs for hepatocellular carcinoma at present, discussed the development potential of kinds of drugs thoroughly and the challenge they will possibly face in the future, to seek the Combination Therapy methods for advanced hepatocellular carcinoma and prolong the survival time. |
| |
| Keywords: | Hepatocellular carcinoma Treatment molecular target drug multi-drug resistance |
| 本文献已被 维普 等数据库收录！ |
|
